Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years Journal Article
| Authors: | Riedl, C. C.; Slobod, E.; Jochelson, M.; Morrow, M.; Goldman, D. A.; Gonen, M.; Weber, W. A.; Ulaner, G. A. |
| Article Title: | Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years |
| Abstract: | National Comprehensive Cancer Network guidelines consider 18FFDG PET/CT for only clinical stage III breast cancer patients. However, there is debate whether TNM staging should be the only factor in considering if PET/CT is warranted. Patient age may be an additional consideration, because young breast cancer patients often have more aggressive tumors with potential for earlier metastases. This study assessed PET/CT for staging of asymptomatic breast cancer patients younger than 40 y. Conclusion: PET/CT revealed distant metastases in 17% of asymptomatic stage IIB breast cancer patients younger than 40 y. Although guidelines of the National Comprehensive Cancer Network recommend against systemic staging in patients with stage II disease, our data suggest that PET/CT might be valuable in younger patients with stage IIB and III disease. Use of PET/CT in younger patients has the potential to reduce the morbidity and cost of unnecessary therapies in young breast cancer patients. Methods: In this Institutional Review Board-approved retrospective study, our hospital information system was screened for breast cancer patients younger than 40 y who underwent staging PET/CT before any treatment. Patients with symptoms or conventional imaging findings suggestive of distant metastases or with prior malignancy were excluded. Initial stage was based on physical examination, mammography, ultrasound, and breast MR imaging. PET/CT was then evaluated to identify unsuspected extraaxillary regional nodal and distant metastases. Results: One hundred thirty-four patients with initial breast cancer stage I to IIIC met inclusion criteria. PET/CT findings led to upstaging to stage III or IV in 28 patients (21%). Unsuspected extra-axillary regional nodes were found in 15 of 134 patients (11%) and distant metastases in 20 of 134 (15%), with 7 of 134 (5%) demonstrating both. PET/CT revealed stage IV disease in 1 of 20 (5%) patients with initial clinical stage I, 2 of 44 (5%) stage IIA, 8 of 47 (17%) stage IIB, 4 of 13 (31%) stage IIIA, 4 of 8 (50%) stage IIIB, and 1 of 2 (50%) stage IIIC. All 20 patients upstaged to stage IV were histologically confirmed. Four synchronous thyroid and 1 rectal malignancies were identified. |
| Keywords: | adult; controlled study; major clinical study; histopathology; review; cancer staging; nuclear magnetic resonance imaging; lymph node metastasis; staging; breast cancer; cancer screening; retrospective study; distant metastasis; age; mammography; echography; fluorodeoxyglucose f 18; computer assisted emission tomography; thyroid cancer; physical examination; metastases; pet; rectum cancer; fdg; asymptomatic disease; human; female |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 55 |
| Issue: | 10 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2014-10-01 |
| Start Page: | 1578 |
| End Page: | 1583 |
| Language: | English |
| DOI: | 10.2967/jnumed.114.143297 |
| PROVIDER: | scopus |
| PUBMED: | 25214641 |
| PMCID: | PMC4414239 |
| DOI/URL: | |
| Notes: | Export Date: 3 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work